HomeA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Nakaraang pagsara
R$124.93
Sakop ng araw
R$124.93 - R$126.32
Sakop ng taon
R$66.50 - R$130.90
Market cap
61.07B USD
Average na Volume
509.00
P/E ratio
-
Dividend yield
-
Sa balita
Investing.com India
3 araw ang nakalipas
Alnylam Pharmaceuticals stock hits all-time high at 470.0 USD
0.60%
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 773.69M | 17.26% |
Gastos sa pagpapatakbo | 646.94M | 19.24% |
Net na kita | -66.28M | -292.43% |
Net profit margin | -8.57 | -234.77% |
Kita sa bawat share | 0.32 | -42.86% |
EBITDA | -2.26M | -103.54% |
Aktuwal na % ng binabayarang buwis | -87.45% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 2.86B | 8.87% |
Kabuuang asset | 4.57B | 13.88% |
Kabuuang sagutin | 4.32B | 7.54% |
Kabuuang equity | 250.59M | — |
Natitirang share | 131.08M | — |
Presyo para makapag-book | 65.41 | — |
Return on assets | -0.92% | — |
Return on capital | -1.39% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -66.28M | -292.43% |
Cash mula sa mga operasyon | 153.73M | 23.82% |
Cash mula sa pag-invest | -141.38M | -516.56% |
Cash mula sa financing | 53.76M | -59.12% |
Net change in cash | 93.61M | -67.32% |
Malayang cash flow | 135.38M | -50.37% |
Tungkol
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Itinatag
Hun 14, 2002
Website
Mga Empleyado
2,230
